...Dong-A ST and Aptis will present five posters on bispecific ADCs targeting CLDN18.2, HER2, AXL, NECTIN4, and PD-L1. [Google translation] (Korea IT Times) - Mar 25, 2026 - "Among them, the CLDN18.2-targeting ADC, DA-3501 (AT-211), showed strong immune-mediated antitumor effects in gastric cancer models resistant to existing treatments. The bispecific ADC platform is expected to deliver more potent and durable anticancer effects compared to single-target therapies."
Preclinical • Gastric Cancer
|